Ph.D., Carnegie Mellon University, Statistics, 1990.
M.S., Carnegie Mellon University, Statistics, 1987.
B.S., University of Cape Town, Statistics, 1985.
Methods for evaluating diagnostic tests
Modeling and outcomes research in prostate cancer
Modeling impact of PSA screening and other interventions on prostate cancer incidence and mortality
Costs and benefits of prostate cancer screening
Trends in prostate cancer screening and related behaviors
Dr. Ruth (Douglas) Etzioni is a Full Member in Biostatistics of the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center. Her work focuses on the development and implementation of statistical methods for prostate cancer studies. In the past, she has worked on assessing the efficacy of PSA screening from population studies, estimating the frequency of overdiagnosis associated with PSA, evaluating novel prostate cancer biomarkers, and tracking patterns and outcomes of prostate cancer care. Her work in prostate cancer surveillance is conducted as part of the Cancer Intervention and Surveillance Modeling Network (CISNET).
As leader of the biostatistics core for the Northwest Prostate Cancer SPORE, Dr. Etzioni has developed methods for analyzing immunohistochemical studies, and combining results from microarray experiments, while working with SPORE investigators to select the most appropriate design and analysis approaches for a broad array of studies. She is an affiliate investigator on the Data Management Coordination Center for the Early Detection Research Network (EDRN) and continues to work with EDRN statisticians on methods for biomarker development. In addition to these projects, her current interests include modeling the development of resistance to androgen ablation therapy.
American Statistical Association
Institute of Mathematical Statistics
International Biometric Society
Society for Medical Decision Making
Biological correlates of biochemical recurrence free survival using multiple markers in a large tissue microarray cohort.. Annals of clinical and laboratory science. 43(1):11-21.. 2013.
American Cancer Society lung cancer screening guidelines.. CA: a cancer journal for clinicians. 63(2):106-17.. 2013.
Comparative effectiveness of alternative prostate-specific antigen-based prostate cancer screening strategies: model estimates of potential benefits and harms.. Annals of internal medicine. 158(3):145-53.. 2013.
Effects of Screening on Radical Prostatectomy Efficacy: The Prostate Cancer Intervention Versus Observation Trial.. Journal of the National Cancer Institute.. 2013.
Response: Reading between the lines of cancer screening trials: using modeling to understand the evidence.. Medical care. 51(4):304-6.. 2013.
Building better models: if we build them, will policy makers use them? Toward integrating modeling into health care decisions. Medical decision making : an international journal of the Society for Medical Decision Making. 32(5):656-9.. 2012.
Prostate Cancer Mortality following Active Surveillance versus Immediate Radical Prostatectomy.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(19):5471-5478.. 2012.
AUDIT-C Alcohol Screening Results and Postoperative Inpatient Health Care Use.. Journal of the American College of Surgeons. 214(3):296-305.e1.. 2012.
The impact of PLCO control arm contamination on perceived PSA screening efficacy.. Cancer causes & control : CCC. 23(6):827-35.. 2012.
Biopsy follow-up of prostate-specific antigen tests.. American journal of preventive medicine. 42(1):37-43.. 2012.
Increasing use of radical prostatectomy for non-lethal prostate cancer in Sweden.. Clinical cancer research : an official journal of the American Association for Cancer Research. 18(24):6742-6747.. 2012.
Depression and incident lower limb amputations in veterans with diabetes.. Journal of diabetes and its complications. 25(3):175-82.. 2011.
Diagnostic imaging and biopsy use among elderly medicare beneficiaries with hepatocellular carcinoma.. Journal of oncology practice / American Society of Clinical Oncology. 7(3):155-60.. 2011.
What if i don't treat my PSA-detected prostate cancer? Answers from three natural history models. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 20(5):740-50.. 2011.
Influence of publication of US and European prostate cancer screening trials on PSA testing practices.. Journal of the National Cancer Institute. 103(6):520-3.. 2011.
Case-control studies of cancer surveillance procedures.. Journal of clinical epidemiology. 64(1):44.. 2011.
Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates.. Journal of clinical epidemiology. 64(12):1412-7.. 2011.
Association of insurance and race/ethnicity with disease severity among men diagnosed with prostate cancer, National Cancer Database 2004-2006.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology. 19(10):2437-44.. 2010.
Calibrating disease progression models using population data: a critical precursor to policy development in cancer control.. Biostatistics (Oxford, England). 11(4):707-19.. 2010.
What happens after an elevated PSA test: the experience of 13,591 veterans.. Journal of general internal medicine. 25(11):1205-10.. 2010.
American Cancer Society guideline for the early detection of prostate cancer: update 2010.. CA: a cancer journal for clinicians. 60(2):70-98.. 2010.
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(16):2668-73.. 2010.
NCCN clinical practice guidelines in oncology: prostate cancer early detection.. Journal of the National Comprehensive Cancer Network : JNCCN. 8(2):240-62.. 2010.